Amylyx Pharmaceuticals Inc
AMLX
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.3B
Close$
$2.33
93.8% downside
Current Fair Value
93.8% downsideOvervalued by 93.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.30 Billion |
|---|---|
| Enterprise Value | $4.25 Billion |
| Dividend Yield | $1.02 (-) |
| Earnings per Share | $-1.53 |
| Beta | -0.21 |
| Outstanding Shares | 111,196,883 |
Return
| Return on Equity | -63.59% |
|---|---|
| Return on Assets | -57.49% |
| Return on Invested Capital | -63.38% |
Valuation & Multiples
| P/E Ratio | -27.42 |
|---|---|
| PEG | -573.89 |
| Price to Sales | - |
| Price to Book Ratio | 18.73 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -27.57 |
| Enterprise Value to Net Income | -28 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$59,429
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2944▲ 8.60% |
|---|---|
| Total Calls | 537,100▲ 24.76% |
| Total Puts | 158,100▲ 76.25% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 105.86%▲ 2.61% |
|---|---|
| Total Invested | $2.16B▲ 35.98% |
| Investors Holding | 222▲ 41.00% |
ESG Score
No data